MCID: MLR006
MIFTS: 43

Male Reproductive Organ Cancer malady

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Male Reproductive Organ Cancer

Aliases & Descriptions for Male Reproductive Organ Cancer:

Name: Male Reproductive Organ Cancer 12 14
Genital Neoplasms, Male 42 69
Malignant Neoplasm of Male Genital Organ, Site Unspecified 12
Malignant Neoplasm of Male Genital Organ, Unspecified 12
Malignant Neoplasm of Male Genital Organ or Tract 12
Malignant Neoplasm of Male Genital Organ, Nos 12
Malignant Tumor of Male Reproductive System 12
Malignant Neoplasm of Male Genital Organs 12
Malignant Tumor of Male Genital Organ 12
Male Reproductive System Neoplasm 12
Tumor of Male Reproductive System 12
Neoplasm of Male Genital Organ 12
Male Genital Neoplasm 12
Male Genital Cancer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3856
ICD9CM 35 187.9
MeSH 42 D005834
NCIt 47 C3054 C8561

Summaries for Male Reproductive Organ Cancer

Disease Ontology : 12 A reproductive organ cancer that is manifested in the male genital system. This includes organs such as the penis and scrotum.

MalaCards based summary : Male Reproductive Organ Cancer, also known as genital neoplasms, male, is related to prostate cancer and seminal vesicle adenocarcinoma. An important gene associated with Male Reproductive Organ Cancer is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Glioma and Prolactin Signaling Pathway. The drugs Goserelin and Levonorgestrel have been mentioned in the context of this disorder. Related phenotypes are endocrine/exocrine gland and adipose tissue

Related Diseases for Male Reproductive Organ Cancer

Diseases related to Male Reproductive Organ Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 33)
id Related Disease Score Top Affiliating Genes
1 prostate cancer 10.9
2 seminal vesicle adenocarcinoma 10.9
3 littre gland carcinoma 10.9
4 cowper gland carcinoma 10.9
5 testicular germ cell tumor 10.4
6 penile cancer 10.4
7 penis squamous cell carcinoma 10.4
8 paratesticular adenocarcinoma 10.4
9 adenocarcinoma of penis 10.4
10 fuchs' heterochromic uveitis 10.4 AMACR KLK3 NKX3-1
11 exocervical carcinoma 10.4 AR CYP17A1 KLK3
12 colon signet ring adenocarcinoma 10.3 AMACR AR KLK3 TMPRSS2
13 skin hemangioma 10.3 AMACR AR FOLH1 KLK3
14 labyrinthitis 10.3 KLK3 MSMB NKX3-1
15 rhinitis 10.3 AMACR KLK3 TP53
16 reticulosarcoma 10.3 AR TP53
17 malignant pleural solitary fibrous tumor 10.3 AKT1 KLK3 PTEN TP53
18 congenital bile acid synthesis defect 10.3 AR KLK3 TP53
19 nevoid hypermelanosis, linear and whorled 10.3 GSTP1 KLK3 PTEN TP53
20 brown-vialetto-van laere syndrome 10.3 KLK3 TMPRSS2 TP53
21 adult astrocytic tumour 10.3 AKT1 IGF1 PTEN TP53
22 prostate cancer, hereditary, x-linked 1 10.3 AKT1 AR GSTP1 PTEN TP53
23 ovarian brenner tumor 10.3 AKT1 GSTP1 PTEN TP53
24 spinal muscular atrophy with progressive myoclonic epilepsy 10.3 AMACR GSTP1 TP53
25 malt worker's lung 10.2 KLK3 TP53
26 necrobiosis lipoidica 10.2 IGF1 KLK3 TP53
27 rapsn-related fetal akinesia deformation sequence 10.2 AR CYP17A1 KLK3 MSMB NKX3-1 PTEN
28 ovary rhabdomyosarcoma 10.2 KLK3 NKX3-1
29 splenic infarction 10.1 AMACR AR FOLH1 GSTP1 KLK3 MSMB
30 basal cell carcinoma 7 10.1 AKT1 GRP IGF1 PSCA PTEN TP53
31 bardet-biedl syndrome 9.7 AKT1 AMACR AR CYP17A1 FOLH1 GRP
32 split-hand/foot malformation with long bone deficiency 1 9.6 AKT1 AMACR AR CYP17A1 FOLH1 GRP
33 adult medulloblastoma 9.6 AKT1 AMACR AR CYP17A1 FOLH1 GRP

Graphical network of the top 20 diseases related to Male Reproductive Organ Cancer:



Diseases related to Male Reproductive Organ Cancer

Symptoms & Phenotypes for Male Reproductive Organ Cancer

MGI Mouse Phenotypes related to Male Reproductive Organ Cancer:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.81 AKT1 AR IGF1 MSMB NKX3-1 PTEN
2 adipose tissue MP:0005375 9.73 AKT1 AMACR AR IGF1 PTEN TP53
3 neoplasm MP:0002006 9.61 TMPRSS2 TP53 AKT1 AR IGF1 MSMB
4 reproductive system MP:0005389 9.28 AKT1 AR CYP17A1 IGF1 MSMB NKX3-1

Drugs & Therapeutics for Male Reproductive Organ Cancer

Drugs for Male Reproductive Organ Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 860)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Goserelin Approved Phase 4,Phase 3,Phase 2,Phase 1 65807-02-5 47725 5311128
2
Levonorgestrel Approved, Investigational Phase 4,Phase 2 797-63-7, 17489-40-6 13109
3
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 2 71-58-9
4
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
5
Cyproterone Acetate Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 427-51-0
6
Drospirenone Approved Phase 4 67392-87-4 68873
7
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 50-28-2 5757 53477783
8
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Early Phase 1 57-63-6 5991
9
Bicalutamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 90357-06-5 56069 2375
10
Dutasteride Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 164656-23-9 152945 6918296
11
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
12
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-18-4 6010
13
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
14
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53714-56-0 3911 657181
15
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
16
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
17
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
18
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
19
Granisetron Approved, Investigational Phase 4,Phase 3 109889-09-0 3510
20
Histamine Approved, Investigational Phase 4,Phase 2 75614-87-8, 51-45-6 774
21
Lenograstim Approved Phase 4,Phase 2,Phase 3,Phase 1 135968-09-1
22
Ranitidine Approved Phase 4,Phase 1,Phase 2 66357-59-3, 66357-35-5 3001055
23
Ciprofloxacin Approved, Investigational Phase 4,Phase 2 85721-33-1 2764
24
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
25
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 5754 657311
26
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 112809-51-5 3902
27
Flutamide Approved Phase 4,Phase 3,Phase 2,Phase 1 13311-84-7 3397
28
Etidronic acid Approved Phase 4,Phase 3 7414-83-7, 2809-21-4 3305
29
Finasteride Approved Phase 4,Phase 2 98319-26-7 57363
30
Diphenhydramine Approved Phase 4,Phase 3,Phase 2,Phase 1 58-73-1, 147-24-0 3100
31
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
32
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
33
Ondansetron Approved Phase 4,Phase 2 99614-02-5 4595
34
Promethazine Approved Phase 4,Phase 3,Phase 2,Phase 1 60-87-7 4927
35
Fesoterodine Approved Phase 4 286930-02-7, 286930-03-8 6918558
36
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2 137-58-6 3676
37
Prilocaine Approved Phase 4 721-50-6 4906
38
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3 104987-11-3 445643 439492
39
Tadalafil Approved, Investigational Phase 4,Phase 3,Phase 1 171596-29-5 110635
40
Pioglitazone Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 111025-46-8 4829
41
Danazol Approved Phase 4 17230-88-5 28417
42
Menotropins Approved Phase 4,Phase 3 61489-71-2 5360545
43
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 57-83-0 5994
44
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 9004-61-9 53477741 24759
45
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2216-51-5 16666
46
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
47
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
48
Levofloxacin Approved, Investigational Phase 4,Phase 3 100986-85-4 149096
49
Ofloxacin Approved Phase 4,Phase 3 82419-36-1 4583
50
Denosumab Approved Phase 4,Phase 3,Phase 2,Phase 1 615258-40-7

Interventional clinical trials:

(show top 50) (show all 3643)
id Name Status NCT ID Phase
1 Treatment of Localized Prostate Cancer With High Intensity Focused Ultrasound Using the Sonablate® 500 System in Canada Unknown status NCT00573586 Phase 4
2 FINNPROSTATE Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer Unknown status NCT00293670 Phase 4
3 Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy Unknown status NCT01379742 Phase 4
4 Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer Unknown status NCT00906269 Phase 4
5 Early Detection of Prostate Cancer by FACS Unknown status NCT00524823 Phase 4
6 MR-Lymphography and Lymph Node Staging in Prostate Cancer Unknown status NCT00185029 Phase 4
7 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
8 A Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia Unknown status NCT01074892 Phase 4
9 Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications Unknown status NCT01876836 Phase 4
10 Endometrial Scratching During Laproscopic Ovarian Drilling in Subfertile PCOS Women Unknown status NCT02140398 Phase 4
11 Strategies for Ovulation Induction in Anovulatory Infertile Patients With PCOS Unknown status NCT00461643 Phase 4
12 Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants Unknown status NCT02027337 Phase 4
13 the Effect of Diane-35 Pretreatment on In-vitro Fertilization Outcome for Patients With Polycystic Ovary Syndrome Unknown status NCT01752270 Phase 4
14 Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy Completed NCT00470834 Phase 4
15 Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men Completed NCT00363311 Phase 4
16 Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer Completed NCT00859027 Phase 4
17 3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer Completed NCT01296672 Phase 4
18 Study to Monitor the Effects of Androgen Suppression Treatment on the Heart Completed NCT01230905 Phase 4
19 The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy Completed NCT00063609 Phase 4
20 An Alternative to A Fixed Schedule In Management Of Prostate Cancer Completed NCT01056562 Phase 4
21 Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX Completed NCT00590213 Phase 4
22 Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer Completed NCT01511874 Phase 4
23 Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases Completed NCT00219219 Phase 4
24 Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer Completed NCT00219271 Phase 4
25 Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer Completed NCT02074137 Phase 4
26 Docetaxel in the Treatment of Hormone Refractory Prostate Cancer Completed NCT00280098 Phase 4
27 A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates Completed NCT00172016 Phase 4
28 Casodex/Zoladex Biomarkers in Localised Prostate Cancer Completed NCT00293696 Phase 4
29 Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer Completed NCT02441894 Phase 4
30 A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer Completed NCT00220194 Phase 4
31 Evaluate Recovery of Testosterone for Patients Using Eligard Completed NCT01136226 Phase 4
32 Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration Completed NCT01161563 Phase 4
33 Global Performance Evaluation of the AMS CONTINUUM™ Device Completed NCT01083199 Phase 4
34 Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer Completed NCT00199485 Phase 4
35 Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation Completed NCT00805701 Phase 4
36 Effect of Soy on Cognition and Hot Flashes in Men With Prostate Cancer Undergoing Testosterone Suppression Therapy Completed NCT00245518 Phase 4
37 Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer Completed NCT00375765 Phase 4
38 A Study of the Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic Prostatectomy Completed NCT01661166 Phase 4
39 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism Completed NCT02102646 Phase 4
40 Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis Completed NCT00035997 Phase 4
41 Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases Completed NCT00434317 Phase 4
42 Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy Completed NCT00237146 Phase 4
43 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4
44 Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer Completed NCT00391690 Phase 4
45 Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis Completed NCT00237159 Phase 4
46 Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer Completed NCT01649635 Phase 4
47 Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases Completed NCT00242554 Phase 4
48 Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed NCT00029224 Phase 4
49 Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer Completed NCT00334139 Phase 4
50 Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer Completed NCT00953277 Phase 4

Search NIH Clinical Center for Male Reproductive Organ Cancer

Cochrane evidence based reviews: genital neoplasms, male

Genetic Tests for Male Reproductive Organ Cancer

Anatomical Context for Male Reproductive Organ Cancer

Publications for Male Reproductive Organ Cancer

Variations for Male Reproductive Organ Cancer

Expression for Male Reproductive Organ Cancer

Search GEO for disease gene expression data for Male Reproductive Organ Cancer.

Pathways for Male Reproductive Organ Cancer

Pathways related to Male Reproductive Organ Cancer according to GeneCards Suite gene sharing:

(show all 24)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.67 AKT1 AR GSTP1 IGF1 KLK3 NKX3-1
2
Show member pathways
12.37 AKT1 CYP17A1 PTEN SHC4
3
Show member pathways
12.28 AKT1 IGF1 PTEN TP53
4
Show member pathways
12.25 AKT1 IGF1 PTEN TP53
5 12.15 AKT1 AR GSTP1 IGF1 KLK3 NKX3-1
6 11.98 AKT1 AR PTEN TP53
7
Show member pathways
11.88 AKT1 AR IGF1 KLK3 PTEN
8 11.8 AKT1 IGF1 PTEN TP53
9 11.76 IGF1 PTEN RNASEL TP53
10 11.72 AKT1 PTEN TP53
11 11.71 AKT1 PTEN TP53
12 11.66 AKT1 AR KLK3 PTEN
13 11.62 AKT1 GSTP1 TP53
14 11.57 AKT1 PTEN TP53
15 11.56 AKT1 PTEN TP53
16 11.52 IGF1 KLK2 KLK3
17 11.46 AKT1 PTEN TP53
18 11.39 KLK2 KLK3 KLK4
19
Show member pathways
11.36 AR KLK3 NKX3-1
20 11.35 AKT1 PTEN TP53
21 11.26 AR KLK2 KLK3 TMPRSS2
22 11.14 AKT1 IGF1 PTEN
23 10.87 IGF1 KLK2 KLK3
24 10.86 AKT1 AR KLK2 KLK3 NKX3-1 TMPRSS2

GO Terms for Male Reproductive Organ Cancer

Cellular components related to Male Reproductive Organ Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.32 GRP GSTP1 IGF1 KLK2 KLK3 KLK4

Biological processes related to Male Reproductive Organ Cancer according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.93 AKT1 GSTP1 IGF1 PTEN TP53
2 positive regulation of cell proliferation GO:0008284 9.92 AR IGF1 NKX3-1 PTEN SHC4
3 cell proliferation GO:0008283 9.77 AKT1 AR IGF1 PTEN TP53
4 cellular response to insulin stimulus GO:0032869 9.69 AKT1 GSTP1 PTEN
5 negative regulation of epithelial cell proliferation GO:0050680 9.58 AR NKX3-1 PTEN
6 positive regulation of glycogen biosynthetic process GO:0045725 9.57 AKT1 IGF1
7 insulin-like growth factor receptor signaling pathway GO:0048009 9.56 AKT1 IGF1
8 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.55 AR IGF1
9 negative regulation of cell size GO:0045792 9.49 AKT1 PTEN
10 cellular response to steroid hormone stimulus GO:0071383 9.48 AR NKX3-1
11 prostate gland development GO:0030850 9.46 AR NKX3-1
12 phosphatidylinositol-mediated signaling GO:0048015 9.46 AKT1 IGF1 PTEN TP53
13 prostate gland growth GO:0060736 9.43 AR PTEN
14 negative regulation of extrinsic apoptotic signaling pathway GO:2001237 9.43 AR GSTP1 IGF1
15 cellular response to decreased oxygen levels GO:0036294 9.32 AKT1 PTEN
16 cellular response to hypoxia GO:0071456 9.26 AKT1 NKX3-1 PTEN TP53
17 protein kinase B signaling GO:0043491 8.92 AKT1 IGF1 NKX3-1 PTEN

Molecular functions related to Male Reproductive Organ Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 peptidase activity GO:0008233 9.65 FOLH1 KLK2 KLK3 KLK4 TMPRSS2
2 serine-type endopeptidase activity GO:0004252 9.46 KLK2 KLK3 KLK4 TMPRSS2
3 serine-type peptidase activity GO:0008236 9.26 KLK2 KLK3 KLK4 TMPRSS2
4 androgen receptor activity GO:0004882 8.62 AR NKX3-1

Sources for Male Reproductive Organ Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....